Seeking Alpha
 

Novartis AG (NVS)

- NYSE
  • Yesterday, 8:06 AM
    • Arrowhead Research (NASDAQ:ARWR) acquires Novartis' (NYSE:NVS) RNA interference (RNAi) R&D portfolio and associated assets, including certain patents and patent applications, an exclusive license to other patents and patent applications owned or controlled by Novartis, the assignment of a third party license and three preclinical product candidates.
    • Specific assets include multiple patent families covering RNAi-trigger design rules and modifications that fall outside of competitors' patents which provides Arrowhead freedom to operate for any target or indication, the assignment of Novartis' license from Alnylam (NASDAQ:ALNY) that gives Arrowhead access to Alnylam IP, excluding delivery, covering 30 gene targets and three product candidates with varying amounts of preclinical data.
    • Under the terms of the agreement, Arrowhead will pay $10M in cash (includes $7M paid previously) and $25M in ARWR stock within 30 days. Novartis is eligible to receive milestones and single-digit royalties on net sales.
    • Arrowhead will host a conference call this morning at 8:30 am to discuss the deal.
    | 1 Comment
  • Wed, Mar. 4, 11:39 PM
    • Both boards have signed off on AbbVie's (NYSE:ABBV) $21B surprise acquisition of Pharmacyclics (NASDAQ:PCYC), announced a short while ago amid speculation that Johnson & Johnson (NYSE:JNJ) (or, earlier, Novartis (NYSE:NVS)) would be the one to acquire the cancer biotech.
    • With the deal, AbbVie gets Pharmacyclics' blockbuster Imbruvica drug for hematologic malignancies -- which logged $548M in revenues in 2014 (Q4 earnings) and might go all the way to $5B/year. Imbruvica has received four indications in less than 15 months -- the latest being for Waldenström's Macroglobulinemia at the end of January.
    • And with Imbruvica, AbbVie can lessen its reliance on its key drug Humira, an aging rheumatoid arthritis medication.
    • The acquisition is expected to close in the middle of the year.
    • Question: What happened to Pharmacyclics' Imbruvica partner JNJ on this deal?
    • Previously: Pharmacyclics Q4 revenue up 135%, Imbruvica growing exponentially (Feb. 18 2015)
    | 27 Comments
  • Mon, Mar. 2, 2:58 AM
    • GlaxoSmithKline (NYSE:GSK) and Novartis (NYSE:NVS) have completed a series of asset swaps worth more than $20B that will reshape both drugmakers.
    • Glaxo is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis.
    • Following completion of the transactions, Glaxo plans to return £4B ($6.16B) to shareholders.
    • Previously: Novartis announces billions of dollars in deals with GSK, Eli Lilly (Apr. 22 2014)
    | Comment!
  • Wed, Feb. 25, 1:43 PM
    • Pharmacyclics (PCYC +17%) jumps on a 4x surge in volume on news that it is considering selling itself. Novartis (NVS +0.2%) and Johnson & Johnson (JNJ -0.1%) are rumored to be in the mix.
    | 17 Comments
  • Wed, Feb. 25, 12:36 PM
    • Citing good progress in obtaining clearances and approvals, GlaxoSmithKline (GSK +0.1%) expects to complete its three-part deal with Novartis (NVS -0.2%) sometime during the first week in March.
    • The transaction, first announced in April of last year, consists of GSK buying NVS's vaccines business, the creation of a consumer healthcare joint venture between the two firms and the sale of GSK's marketed oncology portfolio to NVS, including related R&D and the rights to two AKT inhibitors in development.
    • Previously: Novartis announces billions of dollars in deals with GSK, Eli Lilly (April 22, 2014)
    | Comment!
  • Mon, Feb. 23, 12:42 PM
    • The Federal Trade Commission in the U.S. approves Novartis' (NVS +0.1%) purchase of GlaxoSmithKline's (GSK -0.1%) oncology business for $16B, contingent on the divestment of the BRAF and MEK inhibitors.
    • Previously: Why Glaxo bids adieu to cancer drugs (April 22, 2014)
    | Comment!
  • Thu, Feb. 5, 8:12 AM
    • GlaxoSmithKline (NYSE:GSK) commences an offering of its entire stake of 4,471,202 shares (7.9%) of Danish biotech GenMab. The company is selling its position because it no longer considers it a core asset since it sold its oncology portfolio to Novartis (NYSE:NVS).
    • The outcome of the divestment should be announced today.
    | Comment!
  • Thu, Jan. 15, 7:22 AM
    • In an effort to increase its focus on developing new drugs, privately-held Boehringer Ingelheim says that it is considering the sale of Roxane Labs, its U.S.-based generics unit. The company believes it makes more sense for a generics specialist to own the 1,300-employee business.
    • The generics industry is fiercely competitive as the number of blockbuster drugs coming off patent has declined from its peak in 2012. The top players are (NYSE:TEVA), Sandoz (NYSE:NVS) and Actavis (NYSE:ACT).
    • According to Bloomberg, Roxane could fetch as much as $2.4B. Morgan Stanley is advising.
    | Comment!
  • Thu, Jan. 1, 9:27 AM
    • Novartis (NYSE:NVS) has completed the $5.4B sale of its animal-health division to Eli Lilly (NYSE:LLY).
    • The sale of the unit is part of a complex overhaul at NVS that will focus the company on three core businesses: innovative pharmaceuticals, eye care, and generics.
    • As a result of the transaction, Novartis will record an exceptional pretax gain of about $4.6B in Q1 of 2015.
    | 2 Comments
  • Nov. 26, 2014, 3:48 PM
    • The Federal Trade Commission approves GlaxoSmithKline's (GSK +0.4%) proposed acquisition of Novartis' (NVS +0.6%) vaccines business and the proposed creation of a consumer healthcare joint venture between the two firms.
    • As a condition of the positive vote, Novartis will divest its private label nicotine replacement therapy transdermal patch, Habitrol, in the U.S. to Dr. Reddy's Laboratories SA (RDY +1.5%).
    | Comment!
  • Nov. 24, 2014, 7:05 AM
    | Comment!
  • Oct. 27, 2014, 6:43 AM
    • Novartis (NYSE:NVS) sells its global influenza vaccine business to Australian blood products firm CSL Ltd. for $275M. The transaction, part of Novartis' effort to focus on its most promising assets, concludes the company's overhaul of its units. The deal is expected to close in 2H 2015.
    • Earlier this year, GlaxoSmithKline (NYSE:GSK) bought its vaccine business, ex-flu, for $5.25B plus milestones up to $1.8B and royalties.
    | Comment!
  • Oct. 3, 2014, 7:45 AM
    • The European Commission approves Eli Lilly's (NYSE:LLY) acquisition of Novartis' (NYSE:NVS) Animal Health business. Its investigation found that the proposed transaction does not raise competition concerns due to the presence of other prominent competitors.
    | Comment!
  • Sep. 1, 2014, 8:20 AM
    • EU antitrust authorities will decide whether to clear Eli Lilly's (NYSE:LLY) $5.4B offer for Novartis' animal health division (NYSE:NVS) by Oct. 3.
    • The acquisition is part of several deals recently announced in the healthcare industry, and would create the world's second-largest animal health company.
    | 1 Comment
  • Aug. 19, 2014, 7:14 AM
    • Novartis (NYSE:NVS) buys a 15% stake in Gamida Cell, an Israeli developer of stem cell therapies, for $35M and receives an option to acquire the company from parent Elbit Imaging. The buyout is linked to the achievement of development milestones for NiCord, a treatment for hematologic diseases such as leukemia, lymphoma and sickle cell disease.
    • If Novartis exercises its option, it would pay $165M in cash and up to $435M in milestone payments. The option expires in 1H 2016.
    • NiCord is currently in Phase 1/2 clinical trials.
    | Comment!
  • May. 11, 2014, 2:30 AM
    • Sanofi (SNY), Johnson & Johnson (JNJ) and other major pharmaceutical companies have rebuffed Allergan's (AGN) inquiries as to whether they would be interested in buying the botox maker, Bloomberg reports.
    • Sanofi isn't interested, while J&J is concerned about the problems of combining the two biggest makers of breast implants in the U.S. Allergan has also approached GlaxoSmithKline (GSK) and Novartis (NVS).
    • Allergan contacted the possible suitors as it's not happy with an acquisition offer of $45.7B from Valent (VRX) that is being supported by Bill Ackman's Pershing Square.
    • Some of the firms that Allergan has approached would possibly buy parts of the company, but not the whole business.
    | 3 Comments
Visit Seeking Alpha's
NVS vs. ETF Alternatives
Company Description
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.